Dr. Brad Reinfeld, MD PhD

MSKCC Oncology Fellow, Former Vanderbilt MSTP/UCLA Intern. Bass player in the CheckPoints. Physician-scientist studying metabolism. Views are my own! 🏳️‍🌈🩺

[Tennessean @Tennessean]

Jefferson Street Sound Museum founder Lorenzo Washington dies at 83 https://t.co/uRT5PpMAVR

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 NICHE-2 | Phase II | dMMR colon cancer 🇳🇱

👥 111 pts | Nivo + ipi → surgery
🎯 3-y DFS 100%
📈 5-y OS 100%
🩸 ctDNA clearance 82% pre-op
✅ All ctDNA− post-op
⚠️ Single-arm trial

💡 Remarkable long-term outcomes!

🔗 https://t.co/3GaKLGGbgj

@OncoAlert

[Joel M. Topf, MD FACP @kidney_boy]

97% risk reduction for composite outcome!

[Dr. Brad Reinfeld, MD PhD @BReinfeld]

@S_Corcoran Just imagine snow

[Hematopoiesis News @Hema_News]

🥼Scientists have developed a massively parallel single-cell #CRISPR screening platform in primary human #hematopoietic stem and progenitor cells, capturing known associations and functional annotation of regulator-phenotype relationships.

Read more in @CellStemCell: https://t.co/2I81KYdhV9.

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Site-specific metabolic and hypoxia-associated profiles in metastatic melanoma" https://t.co/ap2xa8OdjU

[Hematopoiesis News @Hema_News]

Drs. Jennifer Marvin-Peek & Farhad Ravandi summarize the evolving therapeutic landscape of #AML, including current intensive and lower-intensity treatment backbones, approved molecularly targeted therapies, and emerging investigational strategies. 💊

https://t.co/heUkxJsGoW | @SpringerNature

#OpenAccess #AcuteMyeloidLeukemia

[Nico Gagelmann @NicoGagelmann]

Really excited to share the first comprehensive study of germline DDX41 in MDS undergoing transplantation in @BloodPortfolio .

Grateful to Coleman Lindsley, germline brain Chris Reilly @DanaFarber and whole team from @CIBMTR 🙏❤️

https://t.co/QDulZfIjee

[Ed Reznik @EdReznik]

After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab https://t.co/PizrA8NyaU @NatureMedicine

[BWFUND @BWFUND]

From nature reviews cancer - Mapping the functional dark proteome in cancer
https://t.co/DZAtO2aWG7 #bwfcams

[Toni Choueiri, MD @DrChoueiri]

New @jclinicalinvest study led by @BraunMDPhD @YaleCancer and super star Dr Madsen : HIF-2α inhibition with belzutifan preserves T-cell effector function in ccRCC—supporting the rationale for combining HIF-2α and PD-1 blockade without compromising T-cell activity.

Reassuring translational evidence!

https://t.co/lteUZK0Zwc

[Dr. Brad Reinfeld, MD PhD @BReinfeld]

@fabermdphd I bet it’s better!

[Mostafa Faisal @MostafaFaisal14]

A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma
https://t.co/XCeHgDrCoN

[David H Aggen, MD PhD @Dr_Aggen]

There is growing evidence that Nectin-4 expression matters for EV/P response.

We discuss new data linking Nectin-4 expression with treatment outcomes—and what this could mean for biomarker-driven use of EV/P.

Delighted to collaborate with @niklas_kluemper @Markuseckstein3 @DrRosenbergMSK on this @EUplatinum editorial.

Read it here: https://t.co/z4IhfRq9Er

[Aponia_Analytics @AponiaAnalytics]

T-cell numbers may matter less than their neighborhood.

ICI-responsive melanoma was not simply richer in activated lymphocytes. The distinguishing feature was spatial organization: clonally expanded CD8⁺ tumor-resident T cells, CD4⁺ resident T cells and DC3 dendritic cells assembled into local immune triads found only in responding tumors.

TCF1⁺ progenitor-like resident CD8⁺ cells were also enriched, suggesting these niches may continuously replenish cytotoxic effectors rather than merely host terminally activated cells.

The counterpoint is equally interesting. Resistant tumors still carried strong IFN-γ programs, but alongside exhaustion and an immunosuppressive macrophage state.

So an “inflamed” tumor is not necessarily an effective one. The relevant variable may be whether inflammation is organized into a functional local circuit connecting dendritic cells, helper T cells and renewable cytotoxic T cells.

The study is associative—32 lymph-node metastases included only six ICI responders—and cannot establish that these triads cause response.

But it argues that spatial immune architecture may be a more informative biomarker than T-cell abundance or IFN-γ signaling alone.
#immunotherapy #T_cell #Australia
https://t.co/GnrGBynwvg

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Tomorrow at #IMS26: MSK myeloma specialist @UrviShahMD will present research on targeting a metabolic-epigenetic axis to improve CAR T therapy in multiple myeloma. @Myeloma_Society

🗓️ Saturday, September 26 | 11 a.m. BT / 6 a.m. ET

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer" https://t.co/f0FtfXzu47

[Columbia Medicine @ColumbiaMed]

Aaron Viny, MD (@TheDoctorIsVin) was diagnosed with acute lymphoblastic leukemia (ALL) at age 20. More than two decades later, Dr. Viny is a physician-scientist, leukemia specialist, and researcher at Columbia, where the questions he once faced as a patient now influence the therapies he provides and the research he leads. https://t.co/MbEdBbo6MX

[Bloodman @Bloodman]

Big news - Jehovah’s Witnesses can receive PRBC, platelets FFP etc if they want https://t.co/rHpn3kYI8n

[Dr. Brad Reinfeld, MD PhD @BReinfeld]

@ZiadBakouny @ICIFund @CAIAorg @Cycle4Survival @EdReznik Saw a patient yesterday discussing M1 NED treatment Pembro Belz 3 years after nephrectomy with recent wedge for new isolated met. Hard to conclusively say Benefit>>>Risk. Super exciting that we’re getting closer to predicting the risk part. Great work!!!